BSE and BCOS Guideline for Transthoracic Echocardiographic Assessment of Adult Cancer Patients Receiving Anthracyclines and/or Trastuzumab.
BSE and BCOS Guideline for Transthoracic Echocardiographic Assessment of Adult Cancer Patients Receiving Anthracyclines and/or Trastuzumab.
复制标题
BSE和BCOS指南：接受蒽环类药物和/或曲妥珠单抗治疗的成人癌症患者的经胸超声心动图评估。
DOI：
10.1016/j.jaccao.2021.01.011
复制
发表时间：
2021-03
期刊：
影响因子：
--
通讯作者：
British Society of Echocardiography (BSE) and theBritish Society of Cardio-Oncology (BCOS)
中科院分区：
文献类型：
--
作者：
Dobson R;Ghosh AK;Ky B;Marwick T;Stout M;Harkness A;Steeds R;Robinson S;Oxborough D;Adlam D;Stanway S;Rana B;Ingram T;Ring L;Rosen S;Plummer C;Manisty C;Harbinson M;Sharma V;Pearce K;Lyon AR;Augustine DX;British Society of Echocardiography (BSE) and theBritish Society of Cardio-Oncology (BCOS)
心血管肿瘤学的子专业旨在降低癌症患者或癌症治疗后的心血管发病率和死亡率。癌症治疗可导致多种心血管并发症，包括左心室收缩功能障碍、心包疾病和心脏瓣膜病。超声心动图是诊断和监测许多这些并发症的关键诊断成像工具。对接受蒽环类和/或人表皮生长因子受体（HER）2阳性靶向治疗（例如，曲妥珠单抗和帕妥珠单抗）在接受超声心动图检查的心脏肿瘤患者中占很大比例。英国超声心动图学会和英国肿瘤学会的这份指南概述了接受蒽环类药物和/或曲妥珠单抗治疗的患者的基线和监测超声心动图方案。图像采集的方法和技术的优点和缺点进行了讨论。超声心动图定义考虑癌症治疗相关的心功能不全也提出。肿瘤患者在超声心动图要求中所占比例越来越大。准确评估左室收缩功能对这一患者组的决策至关重要。在这些患者的超声心动图评估中应使用2D LVEF、3D LVEF、GLS和RV评估。潜在心脏毒性癌症治疗的GLS显著下降的临床意义需要进一步研究。
The subspecialty of cardio-oncology aims to reduce cardiovascular morbidity and mortality in patients with cancer or following cancer treatment. Cancer therapy can lead to a variety of cardiovascular complications, including left ventricular systolic dysfunction, pericardial disease, and valvular heart disease. Echocardiography is a key diagnostic imaging tool in the diagnosis and surveillance for many of these complications. The baseline assessment and subsequent surveillance of patients undergoing treatment with anthracyclines and/or human epidermal growth factor receptor (HER) 2-positive targeted treatment (e.g., trastuzumab and pertuzumab) form a significant proportion of cardio-oncology patients undergoing echocardiography. This guideline from the British Society of Echocardiography and British Cardio-Oncology Society outlines a protocol for baseline and surveillance echocardiography of patients undergoing treatment with anthracyclines and/or trastuzumab. The methodology for acquisition of images and the advantages and disadvantages of techniques are discussed. Echocardiographic definitions for considering cancer therapeutics-related cardiac dysfunction are also presented. Cardio-oncology patients account for an increasing proportion of echocardiography requests. Accurate assessment of LV systolic function is critical to decision-making in this patient group. 2D LVEF, 3D LVEF, GLS, and RV assessment should be used in the echocardiographic assessment of these patients. The clinical implications of a significant decline in GLS with potentially cardiotoxic cancer therapy require further investigation.
登录
查看更多内容
DOI：
10.1186/s40959-016-0014-2
发表时间：
2016-04-19
期刊：
Cardio-oncology (London, England)
影响因子：
--
作者：
Barros-Gomes, Sergio;Herrmann, Joerg;Villarraga, Hector R
通讯作者：
Villarraga, Hector R
影响因子：
18.2
作者：
Eschenhagen, Thomas;Force, Thomas;Shah, Ajay M.
通讯作者：
Shah, Ajay M.
影响因子：
5.4
作者：
Addison D;Campbell CM;Guha A;Ghosh AK;Dent SF;Jneid H
通讯作者：
Jneid H
影响因子：
45.3
作者：
Ewer, MS;Vooletich, MT;Lenihan, DJ
通讯作者：
Lenihan, DJ
影响因子：
45.3
作者：
Armenian, Saro H.;Lacchetti, Christina;Lenihan, Daniel
通讯作者：
Lenihan, Daniel